Short Interest in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Decreases By 23.6%

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 78,900 shares, a decline of 23.6% from the November 15th total of 103,300 shares. Based on an average trading volume of 2,830,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 2.9% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Maxim Group cut their price objective on shares of Theriva Biologics from $25.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Theriva Biologics stock. Anson Funds Management LP acquired a new position in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned 6.13% of Theriva Biologics as of its most recent SEC filing. Institutional investors and hedge funds own 6.17% of the company’s stock.

Theriva Biologics Trading Down 0.8 %

Shares of NYSEAMERICAN TOVX traded down $0.01 during trading hours on Friday, hitting $1.18. 50,433 shares of the stock were exchanged, compared to its average volume of 928,365. The firm has a market capitalization of $3.28 million, a price-to-earnings ratio of -0.04 and a beta of 1.33. Theriva Biologics has a 1-year low of $1.14 and a 1-year high of $17.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its earnings results on Tuesday, November 12th. The company reported ($6.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.25) by ($0.56).

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.